Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination immunization regimen consisting of the MenACWY-PS polysaccharide vaccine and the conjugate meningococcal vaccine, Menveo. The MenACWY-PS (polysaccharide) vaccine contains purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, Y, and W-135. It induces immunity by stimulating the production of bactericidal antibodies against these serogroups through a T-cell independent mechanism. Menveo is a quadrivalent conjugate vaccine containing oligosaccharides from Neisseria meningitidis serogroups A, C, Y, and W-135 conjugated to diphtheria CRM197 protein. It induces immunity via a T-cell dependent response that promotes immunologic memory and higher antibody titers compared to pure polysaccharide vaccines[2][6][9]. The combination may be used in certain clinical or public health settings where both immediate protection (from PS) and longer-term memory (from conjugate) are desired or for catch-up/booster strategies[6]. Both components are indicated for prevention of invasive disease caused by Neisseria meningitidis serogroups A, C, Y, and W.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MenACWY-PS polysaccharide vaccine + Menveo.